SH2B1 gene defends against obesity via the paraventricular hypothalamus

FHS
July 15, 2024
7:38 pm

Obesity is a complicated condition, caused by a combination of genetics, the food environment, behavior, and other factors.

Merck KGaA’s bet on head and neck cancer drug from Debiopharm ends in Phase 3 failure

Merck KGaA’s Phase 3 trials of xevinapant, the cancer drug it licensed from Debiopharm in 2021, are winding down after the drug showed that it

June 25, 2024

Roche CEO explains the company’s weight loss drug strategy in crowded market

LONDON — In the booming field of weight loss drugs, Roche has been riding high in recent months, with back-to-back positive studies of two experimental

July 25, 2024

Vendor Sprawl: The Hidden Barrier to Effective Patient Engagement

Aditya Bansod, Chief Technology Officer, Luma Health Patient engagement is a critical priority for modern healthcare organizations. Yet, the path is often obstructed by the

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.